Rights and permissions
About this article
Cite this article
Eisai to appeal SMC's decision not to recommend Halaven. Pharmacoecon. Outcomes News 640, 10 (2011). https://doi.org/10.2165/00151234-201106400-00034
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106400-00034